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Background: Changes in β-amyloids (Aβ) and tau proteins have been noted in patients
with Alzheimer’s disease (AD) and patients with both Down syndrome (DS) and AD.
However, reports of changes in the early stage of regression, such as behavioral and
psychological symptoms of dementia (BPSD), in DS are sparse.
Methods: Seventy-eight controls, 62 patients with AD, 35 with DS and 16 with DS
with degeneration (DS_D), including 9 with BPSD and 7 with dementia, were enrolled.
The levels of β-amyloids 40 and 42 (Aβ-40, Aβ-42) and tau protein in the blood were
analyzed using immunomagnetic reduction (IMR). The Adaptive Behavior Dementia
Questionnaire (ABDQ) was used to evaluate the clinical status of the degeneration.
Results: The Aβ-40 and tau levels were higher and the Aβ-42 level and Aβ-42/Aβ-40
ratio were lower in DS than in the controls (all p < 0.001). Decreased Aβ-40 and
increased Aβ-42 levels and Aβ-42/40 ratios were observed in DS_D compared with
DS without degeneration (all p < 0.001). The ABDQ score was negatively correlated
with the Aβ-40 level (ρ = −0.556) and the tau protein level (ρ = −0.410) and positively
associated with the Aβ-42 level (ρ = 0.621) and the Aβ-42/40 ratio (ρ = 0.544; all
p < 0.05).
Conclusions: The Aβ-40 and Aβ-42 levels and the Aβ-42/Aβ-40 ratio are considered
possible biomarkers for the early detection of degeneration in DS. The elevated Aβ-40
Abbreviations: Aβ, amyloid beta; ABDQ, Adaptive Behavior Dementia Questionnaire; AD, Alzheimer’s disease; APP,
amyloid beta (A4) precursor protein; BPSD, behavioral and psychological symptoms of dementia; CDR, clinical
dementia rating; CSF, cerebrospinal fluid; DMR, Dementia Questionnaire for Mentally Retarded Persons;
DS, Down syndrome; DS_D, Down syndrome with degeneration; DSDS, Dementia Scale for Down Syndrome;
DSQIID, Dementia Screening Questionnaire for Individuals with Intellectual Disabilities; IMR, immunomagnetic
reduction; RADD, Rapid Assessment for Developmental Disabilities; ROC, receiver operating characteristic;
SQUID, superconducting quantum interference device.
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and tau levels in DS may indicate early neurodegeneration. The increased Aβ-42 in
DS_D may reflect the neurotoxicity of Aβ-42. The paradox of the tau decreases in DS_D
could be explained by a burnout phenomenon during long-term neurodegeneration. The
different patterns of the plasma beta amyloids and tau protein may imply a different
pathogenesis between DS with degeneration and AD in the general population, in spite
of their common key pathological features.
Keywords: β-amyloids, Down syndrome, behavioral and psychological symptoms of dementia, Alzheimer’s
disease, dementia, tau protein
INTRODUCTION
Down syndrome (DS), or trisomy 21, is the most common
aneuploidy associated with mental retardation, with an incidence
of approximately 1 in 800 (Lin et al., 1991; Nussbaum et al.,
2001; Centers for Disease Control and Prevention (CDC),
2006). In addition to characteristic facial features, hypotonia,
congenital heart disease, gastrointestinal anomalies and learning
disabilities, people with DS over 35 years old often suffer from
a general acceleration of the aging process, including premature
menopause, presbycusis, alopecia, premature graying of the
hair, dementia, congestive heart failure, atherosclerosis, diabetes,
hypercholesterolemia and hypertension. The close link between
the DS phenotype and an increased risk of developing dementia
has been addressed previously (Bush and Beail, 2004). The
incidence of dementia among DS patients is 8% in the age
range of 35–49 years, 55% in the age range 50–59 years and
75% above the age of 60 years (Zana et al., 2007). Owing to
the extra copy of chromosome 21, several of the 500 genes on
chromosome 21 are overexpressed (Mao et al., 2005), including
the APP gene, which encodes the amyloid beta (A4) precursor
protein (APP).
APP is a membranous protein cleaved by different secretases
to form smaller fragments (peptides), some of which are released
outside the cells (Zheng and Koo, 2011; Kandimalla et al.,
2012). Aβ-40 and Aβ-42 constitute the majority of the released
amyloid beta peptides and are produced through a combination
of sequential β and γ secretase activities (Selkoe, 1994). Thus,
the presence of an extra copy of the APP gene leads to the
overproduction of Aβ peptides in the brain and peripheral
blood in DS (Granic et al., 2010). In Alzheimer’s disease (AD),
elevations of Aβ-42 and tau are observed, and increased Aβ-40 in
the plasma has been described as one of the biomarkers for AD.
In DS, the amyloid plasma levels of Aβ-40 and Aβ-42 are higher
than those of age-matched controls (Coppus et al., 2012). A
higher Aβ-42 level was proposed to be related to the earlier onset
of dementia and mortality, although other studies suggested
that a higher Aβ-40 level at baseline predicted the development
of dementia. Although the findings are not consistent between
studies, they still highlight the importance of Aβ-40 and Aβ-42
in the pathogenesis of dementia in people with DS (Head et al.,
2016).
While the deposition of amyloid beta (Aβ) plaques has
been observed in young DS individuals, senile plaques and
neurofibrillary tangles, the pathological hallmarks of AD, are
usually present in DS individuals by the age of 40 (Krasuski
et al., 2002; Zana et al., 2007). It has been well documented that
the total tau and phosphorylated tau (p-tau 181 and p-tau 231)
in the cerebrospinal fluid (CSF) are the main biomarkers for
monitoring cortical axonal degeneration in AD (Hampel et al.,
2010; Kandimalla et al., 2013; Head et al., 2016). Recently, the
concentration of degradation fragments of tau (Tau-A/Tau-C)
in the blood was found to be related to the change in cognitive
function in early AD patients. In DS with dementia, decreased
CSF Aβ-42 and increased tau have been observed (Tapiola et al.,
2001).
Recently, the behavioral and psychological symptoms of
dementia (BPSD) in DS have been considered as early indicators
of clinical dementia (Dekker et al., 2015). However, the diagnosis
of BPSD is challenging in DS because of the underlying
intellectual disabilities, and the assessment of BPSD in DS has
not been well studied (Dekker et al., 2015; Prasher et al., 2015).
We have developed a new technology called immunomagnetic
reduction (IMR), which is capable of assaying molecules at
very low concentrations (Yang et al., 2011; Chiu et al., 2012,
2013, 2014). IMR measures the reduction in the alternating-
current magnetic susceptibility of suspended bio-magnetic
nanoparticles owing to the immunospecific conjugation between
the nanoparticles and Aβ peptides and tau proteins. The
Aβ-42 to Aβ-40 concentration ratio and the tau levels in the
blood are promising parameters or surrogate biomarkers for
evaluating the risk of AD in the general population (Chiu
et al., 2012, 2014). In this study, ultra-sensitive IMR was
used to assay the plasma Aβ-40, Aβ-42 and tau levels in DS
patients. This assay should help us delineate the abnormal
concentrations of Aβ-40, Aβ-42 and tau in the blood, which
should facilitate the diagnosis of BPSD and dementia in DS.
We sought to evaluate the blood amyloid peptides and tau
protein in subjects with DS and DS with degeneration (both
BPSD and dementia) and to compare these patients with the
subjects with AD. The purposes of this study were to explore the
changes in blood amyloid and tau in DS and to detect the early
deterioration in DS, which could be suggestive of the pathological
changes of AD.
MATERIALS AND METHODS
Participants
This study was approved by the Research Ethics Committee
of National Taiwan University Hospital (No. IRB No.
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201304054RIND, and 201008015R). DS patients who, along
with their guardians, agreed to participate were enrolled.
Informed consent was signed by the participants and/or their
proxy prior to study inclusion in accordance with the Declaration
of Helsinki. Participants with DS (n = 51) were recruited from the
Taiwan DS Foundation and the outpatient clinic of the National
Taiwan University Hospital from August 2010 to December
2015. The diagnosis of DS was made by karyotype analysis when
patients were born with typical clinical presentations. The mean
age of blood sampling was 29.0± 10.6 years (range 13–52 years).
The subjects were asked to provide a 10-ml venous blood sample.
Each sample was assigned a registration number following the
sampling sequence so that the laboratory operators were blind to
the clinical status and the demographic data of the subjects. The
blood samples were centrifuged (2500× g for 15 min) within 1 h
of collection, and the supernatant was aliquoted into cryotubes
and stored at−80◦C until thawed for measurement.
We also included 78 healthy controls (HC) and 62 patients
with AD for comparison. In these groups, the assessments
performed in this study included determining the clinical
dementia rating (CDR) score and the score on the short-form
geriatric depression scale (GDS-S); additionally, the Taiwanese
mental status examination (TMSE) and two subtests of the
Wechsler memory scale (WMS)-III logical memory subtest and
family picture subtest were performed (Hua et al., 2005). For
the HCs, the cognitive assessments of the participants had
to be within normal limits (scores higher than 1.5 standard
deviation) of age- and education-matched normal subjects and
CDR= 0. For the patients with AD, theymustmeet the diagnostic
guidelines for dementia due to AD proposed by the NIA-AA
workgroups in 2011 (Jack et al., 2011; McKhann et al., 2011).
Clinical Assessment for Regression
The Adaptive Behavior Dementia Questionnaire (ABDQ) was
used to evaluate the status of regression of the DS participants
(Prasher et al., 2004). The diagnosis of BPSD was made if
the patient had the clinical presentation of apathy, agitation,
hyperactivity and/or general slowness, depression and psychotic
symptoms (Dekker et al., 2015). Dementia was diagnosed by
an ABDQ score higher than 78 or by a clinical AD diagnosis
according to the degree of cognitive and functional decline;
the clinical diagnosis was performed by an adult neurologist
(MJC) who is an expert in the diagnosis and management
of dementia. DS patients were subgrouped into degeneration
(DS_D) if they were diagnosed as having BPSD or dementia.
The CDR was used to score non-DS populations for AD as a
comparison.
Immunomagnetic Reduction Assay
Aβ-40, Aβ-42 and tau were assayed by IMR with a
high-temperature superconducting quantum interference
device (SQUID) magnetometer, as previously reported. In brief,
3 reagents (MF-AB0-0060, MF-AB2-0060 and MF-TAU-0060,
MagQu, New Taipei City, Taiwan) were used to assay the
biomarkers Aβ-40, Aβ-42 and tau, respectively. These reagents
were then mixed with individual samples. Each mixture was
placed in a SQUID-based alternating-current (ac) magnetic
susceptometer (XacPro-S, MagQu, Taiwan), and the IMR
signals from these samples were detected and converted to the
concentrations of Aβ-40, Aβ-42 and tau using the characteristic
curves. For detailed procedures and technical information,
please refer to our previous reports.
Statistical Analysis
Data were expressed as the mean ± standard deviation. The
Mann-Whitney U test was used. Spearman’s rank correlation
coefficient was used to determine the correlations between the
ABDQ score and the Aβ-42/Aβ-40 ratio and Aβ-40, Aβ-42
and tau levels. P < 0.05 was considered statistically significant.
SPSS (SPSS, Inc., 2008, SPSS Statistics for Windows, Version
17.0. Chicago, IL, USA) was used to conduct receiver operating
characteristic (ROC) curve analysis. The optimal threshold for
the ROC curve was determined by Youden’s index using the
maximum summation of the sensitivity plus specificity with
respect to DS without degeneration as a control (Youden,
1950).
RESULTS
Elevation of Baseline Aβ-40 Levels in DS
Patients Compared to Normal Subjects
The demographic data of the participants are listed in Table 1.
We first divided the HC into younger and older groups. Because
the biomarker levels did not show significant differences, we
combined them into one group (HC). The Aβ-40 level was higher
in DS patients than in healthy subjects (both younger and older
groups), (Table 1, Figure 1A; p < 0.001). However, the Aβ-42
level and the Aβ-42/Aβ-40 ratio were lower in the DS patients
than in the HC (Figures 1B,C; both p < 0.001). Compared to
the HC, individuals with non-DS AD had a lower Aβ-40 level
and a higher Aβ-42 level and Aβ-42/Aβ-40 ratio (p < 0.01,
p = 0.01 and p < 0.01, respectively). This pattern was also
observed in DS subjects. Compared to those with DS without
degeneration, the patients with DS with degeneration (DS_D;
BPSD and dementia) had a lower Aβ-40 level and a higher Aβ-42
level and Aβ-42/Aβ-40 ratio (all p< 0.001).
Correlation Between ABDQ Score and Aβ
Results
ABDQ has been used as a screening tool for dementia in DS. In
our subjects with DS, there were significant differences in the
ABDQ score between subjects with and without degeneration
(BPSD and dementia; Table 1; 60.6 ± 19.8 vs. 25.4 ± 13.8;
p < 0.001). No significant difference was found in the
ABDQ scores between patients with DS with dementia and
those with DS with BPSD (71.8 ± 24.3 vs. 52.1 ± 10.9;
p = 0.080). We found a significant negative correlation between
the Aβ-40 level and ABDQ score (ρ = −0.556; p < 0.001)
and positive associations between the Aβ-42 level (ρ = 0.621),
the Aβ-42/Aβ-40 ratio (ρ = 0.544) and the ABDQ score (both
p< 0.001; Figure 2).
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TABLE 1 | Demographic and biomarker data of the participants.
Group HC_Y HC_E AD DS DS_D
Number 44 34 62 35 16
Female/Male 14/30 20/14 32/29 16/19 6/10
Age (years) 38.4 ± 13.5 70.3 ± 5.8 72.1 ± 11.1 25.6 ± 9.3 35.4 ± 10.7
(range) (23–59) (61–81) (42–93) (13–51) (20–52)
ABDQDS − − − 25.4 ± 13.8 58.8 ± 20.8
CDRAD (n) 0 0 31/19/9/3 − −
Aβ-40 (pg/ml) 61.1 ± 6.3 60.7 ± 6.9 43.9 ± 22.1 129.0 ± 31.8 69.5 ± 31.5
Aβ-42 (pg/ml) 15.8 ± 0.3 16.0 ± 0.5 23.2 ± 18.4 11.3 ± 1.1 20.1 ± 13.2
Aβ-42/Aβ-40 0.26 ± 0.03 0.27 ± 0.04 0.55 ± 0.23 0.10 ± 0.04 0.39 ± 0.38
Tau (pg/ml) 14.9 ± 5.5 15.0 ± 7.3 47.5 ± 18.9 31.5 ± 8.0 26.3 ± 17.3
HC-Y, young healthy controls; HC-E, older healthy controls; DS, Down syndrome; AD, Alzheimer’s disease; DS_D, DS with degeneration (behavioral and psychological
symptoms of dementia (BPSD) or dementia); ABDQ, Adaptive Behavior Dementia Questionnaire; CDR, clinical dementia rating 0.5/1/2/3.
FIGURE 1 | β-amyloids 40 (Aβ-40; AφAβ40) and Aβ-42 (AφAβ42) levels and the Aβ-42/Aβ-40 (AφAβ42/AφAβ40) ratio in healthy controls (HC, combining the
younger and older groups) and in patients with Alzheimer’s disease (AD), Down syndrome (DS) and DS with degeneration (DS_D; behavioral and
psychological symptoms of dementia (BPSD) and dementia). (A) For Aβ-40, p < 0.001 between HC and AD; p < 0.001 between HC and DS;
p < 0.001 between AD and DS; p = 0.497 between HC and DS_D; p < 0.001 between AD and DS_D; and p < 0.001 between DS and DS_D. (B) For Aβ-42,
p < 0.001 between HC and AD; p < 0.001 between HC and DS; p < 0.001 between AD and DS; p = 0.070 between HC and DS_D; p = 0.001 between AD and
DS_D; and p < 0.001 between DS and DS_D. (C) For Aβ-42/Aβ-40, p < 0.001 between HC and AD; p < 0.001 between HC and DS; p < 0.001 between AD and
DS_D; p = 0.888 between HC and DS_D; p < 0.001 between AD and DS; and p < 0.001 between DS and DS_D. ∗∗p < 0.01; ∗∗∗p < 0.001.
FIGURE 2 | Correlation of the Adaptive Behavior Dementia Questionnaire (ABDQ) score with the Aβ-40 (AφAβ40) and Aβ-42 (AφAβ42) levels and the
Aβ-42/Aβ-40 (AφAβ42/AφAβ40) ratio in DS patients (combined DS and DS_D groups). A significant negative correlation between (A) the Aβ-40 level and ABDQ
score (ρ = −0.556; p < 0.001) and (B) positive associations between the ABDQ score and the Aβ-42 level (ρ =0.621; p < 0.001) and (C) Aβ-42/Aβ-40 ratio
(ρ = 0.544; p < 0.001) were noted.
Prediction of Degeneration Using Amyloid
To characterize the diagnostic possibilities, we performed ROC
curve analysis to compare the patients with DS and those
with DS_D (Figure 3). The areas under the curve (AUCs)
of the Aβ-40 and Aβ-42 levels and the Aβ-42/Aβ-40 ratio
were 0.900, 0.937 and 0.902, respectively. The sensitivity and
specificity in differentiating DS from DS_D were 81.3% and
94.3%, respectively, using Aβ-40, with a threshold of 92.2 pg/ml
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(Figures 3A,B); 87.5% and 94.3%, respectively, using Aβ-42, with
a threshold of 12.36 pg/ml (Figures 3C,D); and 81.3% and 91.4%,
respectively, using the Aβ-42/Aβ-40 ratio, with a threshold of
0.13 (Figures 3E,F).
Elevation of Baseline Tau Levels in DS
Patients Compared to Normal Subjects
We also determined the tau concentration in 21 DS participants,
including 9 with DS_D. In the DS subjects, the baseline tau
protein level was higher than that in the HC (Table 1 and
Figure 4A; 31.5± 8.0 vs. 14.9± 5.5 pg/ml; p< 0.001). We found
a significant negative correlation between tau and the ABDQ
score in DS patients (combine DS and DS_D groups; Figure 4B,
ρ = −0.410; p = 0.018). This finding supports the relationship
between cognitive/functional declines and tau profile changes.
However, the ROC curve analysis for differentiating DS from
DS_D using tau yielded an AUC of only 0.49.
DISCUSSION
Because of the baseline cognitive impairment in DS subjects,
it is challenging to diagnose dementia and detect early BPSD
in DS populations. Several assessment tools and questionnaires
can be used to evaluate the signs and symptoms of AD
in DS, including ABDQ, the Dementia Scale for Down
Syndrome (DSDS), the Dementia Screening Questionnaire for
Individuals with Intellectual Disabilities (DSQIID), the Dementia
Questionnaire for Mentally Retarded Persons (DMR) and
the recently developed Rapid Assessment for Developmental
Disabilities (RADD). However, these tools are not satisfactory
because of their ceiling or floor effects. In this study, we not
only used ABDQ to screen DS patients but also employed a
neurologist who specializes in the diagnosis and management
of patients with dementia to evaluate the general behavior
presentation for the diagnosis of AD in DS subjects.
In this study, we demonstrated that compared with healthy
subjects in general, adolescent DS subjects already had elevated
levels of Aβ-40 and tau protein. The baseline elevation of
Aβ-40 in DS adolescents and adults is a reasonable finding
based on the APP protein overexpression in DS, with the
majority of Aβ cleaved into Aβ-40. This finding is consistent
with previous reports (Schupf et al., 2001, 2010; Head et al.,
2011; Coppus et al., 2012). Furthermore, this result suggests
that APP is abnormally cleaved in DS subjects with dementia
and indicates that the underlying pathophysiology of DS with
dementia might be different from that of non-DS patients
with AD.
We also found that the Aβ-40 is decreased and the Aβ-42 and
Aβ-42/Aβ-40 ratio are increased in the blood of DS_D patients.
This observation may imply that with degeneration, a higher
percentage of APP is cleaved into Aβ-42 rather than Aβ-40.
The finding of increases in the Aβ-42 level and Aβ-42/Aβ-40
ratio in DS_D patients is in agreement with previous reports
of observations of non-DS populations with mild cognitive
impairment and AD. In the DS subjects, the majority of reports
demonstrated higher Aβ-42 levels at the baseline compared with
those of HC and a higher Aβ-42 level and Aβ-42/Aβ-40 ratio
in those with DS with dementia. This finding further suggests
that Aβ-42 is a critically toxic substance to the brain in both
groups of subjects with AD, with or without DS. In addition,
we demonstrated a negative correlation between the ABDQ score
and the Aβ-40 level and a positive association between the ABDQ
score and the Aβ-42/Aβ-40 ratio in DS subjects. This correlation
may imply their possible utility as biomarkers to help evaluate the
degeneration in DS.
The tau protein is a microtubule-associated protein located
inside neurons, and hyperphosphorylated tau is the main
component of the neurofibrillary tangles in AD. Because tau
is an intracellular protein, a higher baseline tau level in DS
might indicate early neurodegeneration (neuronal damage), and
tau may consequently be elevated in DS subjects before the
onset of dementia or BPSD. However, we found a negative
correlation between the tau protein and ABDQ and observed a
lower tau level in DS_D. This paradox may be explained by a
possible burnout phenomenon of neurons during the prolonged
neurodegenerative process and a consequently lower level of
tau. A longitudinal study is required to confirm our proposed
explanation.
In this study, we found that the Aβ-40 and Aβ-42 levels and
the Aβ-42/Aβ-40 ratio may be good indicators for the early
detection of degeneration in DS. In our previous reports in a
general population with mild cognitive impairment and AD, the
differential sensitivity and specificity of Aβ-42 and tau between
HC and non-DS AD were approximately 0.9 (0.88–0.97), using
thresholds of 16.33 pg/ml for Aβ-42 and 23.89 pg/ml for tau. The
threshold for Aβ-42 that we used to differentiate DS_D from DS
was 12.36 pg/ml, with a sensitivity of 0.875 and a specificity of
0.943, which was lower than that for non-DS AD. The reason is
not clear but could be the younger age of the DS cohort and the
inclusion of DS with BPSD, which probably represents an early
stage of DS AD. The threshold for tau was 26.04 pg/ml, with a
sensitivity of 0.636 and specificity of 0.8883; this threshold was
higher than that for non-DSAD.However, in DS, the baseline tau
level was higher than in the general population, and a decrease
in tau was noted in DS with AD. These results indicate that
the tau levels that demarcate AD differ between DS AD and
non-DS AD.
This study has some limitations. First, the mean age of
our DS subjects was younger than that of the HC because
of the difficulty of obtaining blood samples from adolescents
for ethical reasons in our hospital. We tried to divide the
HC into two different age groups (ages of 23–59 years and
61–81 years), but the amyloid and tau levels did not exhibit
significant between-group differences. Therefore, we pooled the
results of the healthy subjects from both age groups into one
single group for further analysis to improve the statistical power.
However, this gap could be overcome by evidence from previous
reports that DS subjects have elevated plasma Aβ-40 levels
compared to those of age-matched HC (Schupf et al., 2001,
2010; Head et al., 2011; Coppus et al., 2012). Second, the small
sample size of the subjects of DS with dementia, especially the
number of tau samples, hindered the statistical analysis. Third,
we did not analyze other risk factors for dementia, such as
APP or presenilin (PSEN1 and PSEN2) mutations, although the
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FIGURE 3 | Receiver operating characteristic (ROC) curve of Aβ-40, Aβ-42 and Aβ-42/Aβ-40 for the differential diagnosis of DS without (DS) and with
degeneration (DS_D). (A) ROC curve of Aβ-40. (B) Concentration of Aβ-40 for the differential diagnosis between DS and DS_D. (C) ROC curve of Aβ-42.
(D) Concentration of Aβ-42 for the differential diagnosis between DS and DS_D. (E) ROC curve of Aβ-42/Aβ-40. (F) Concentration of Aβ-42 for the differential
diagnosis between DS and DS_D.
FIGURE 4 | Comparison of tau protein in different groups. (A) Tau protein (φtau) in HC and in subjects with AD, DS or DS with degeneration (BPSD and with
dementia; DS_D). For tau, p < 0.001 between HC and AD; p < 0.001 between HC and DS; p < 0.001 between AD and DS; p = 0.019 between HC and DS_D;
p = 0.001 between AD and DS_D; and p = 0.140 between DS and DS_D. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001. (B) Correlation of the Adaptive Behavior Dementia
Questionnaire (ABDQ) score with the tau. A significant negative correlation between the Aβ-40 level and ABDQ score was noted (ρ = −0.410; p = 0.018).
prevalence of these factors in dementia is extremely low in
the general population. Other possible contributing factors for
dementia should be explored in DS subjects in future studies.
Finally, recent studies revealed that the elevation of tau in the
blood is related to changes in the cognitive function over time in
early AD subjects. In contrast, we observed a decline in tau levels
in DS with degeneration (which were still higher than those of
HC) and proposed a burnout phenomenon of brain tissue from
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the prolonged neurodegeneration process. A longitudinal cohort
study is required to confirm the finding of the tau decline during
the process of DS degeneration.
CONCLUSION
The diagnosis of dementia and/or BPSD in DS is challenging.
This study establishes the capability of differentiating between
DS with and without degeneration. The beta amyloid and tau
levels and the ABDQ score may assist in the early detection of
regression in DS, which might represent an early Alzheimer’s
pathology. However, the different patents of the plasma beta
amyloids and tau protein may imply a different pathogenesis
between DS with degeneration and AD in the general population,
in spite of their common key pathological features.
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